Maravai Lifesciences Holdings, Inc.

Health Care
Biotechnology: Pharmaceutical Preparations
www.maravai.com

Earnings Score
Moat Score
Safety Score

Market Cap $1.05B
PE -6
Debt $535.84M
Cash $573.17M
EV $1.01B
FCF -$16.92M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$162.26M
EBIT	$598.44M
ROE	-21%
ROA	41%
FCF	-$16.92M
Equity	$776.41M
Growth Stability	-109%
PE	-6.48
PEG	2.38
PB	1.35
P/FCF	-62.13
P/S	3.77
Price/Cash	0.55
Debt/Equity	0.69
Debt/FCF	-31.67
Net Margins	-27%
Gross Margins	47%
Op. Margins	215%
Earnings CAGR	-3%
Sales Growth YoY	7%
Sales Growth QoQ	14%
Sales CAGR	-22%
FCF CAGR	-8%
Equity CAGR	69%
Earnings Stability	-0.76
Earnings Growth YoY	21%

Earnings Growth QoQ	-36%
Earnings CAGR 5Y	-3%
Sales CAGR 5Y	-22%
FCF CAGR 5Y	-8%
Equity CAGR 5Y	69%
Earnings CAGR 3Y	-48%
Sales CAGR 3Y	-48%
FCF CAGR 3Y	-26%
Equity CAGR 3Y	17%
Market Cap	$1.05B
Revenue	$278.59M
Assets	$1.45B
Total Debt	$535.84M
Cash	$573.17M
Shares Outstanding	134.09M
EV	1.01B
Earnings Score	6%
Moat Score	35%
Safety Score	38%
Final Score	26%
Working Capital	616.81M
Current Ratio	10
Shares Growth 3y	5%
Equity Growth QoQ	-0%
Equity Growth YoY	-14%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Maravai LifeSciences Holdings Inc is a life sciences company. It provides products to enable the development of drug therapies, diagnostics, novel vaccines and support research on human diseases. The company's segments are Nucleic acid production, Biologics safety testing, and Protein detection. It generates a majority of its revenue from the Nucleic Acid Production that focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.

SEC Filings

Direct access to Maravai Lifesciences Holdings, Inc. (MRVI) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Maravai Lifesciences Holdings, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Maravai Lifesciences Holdings, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR -3%

Stability -76%

loading chart...

Maravai Lifesciences Holdings, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Maravai Lifesciences Holdings, Inc..

Years

Calculation mode

= -$102M

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	-$17M	-$16M	-$14M	-$13M	-$12M	-$11M	-$10M	-$9.6M	-$8.8M	-$8.1M	-$7.5M	-$75M
DCF		-$14M	-$12M	-$10M	-$8.3M	-$7M	-$5.9M	-$4.9M	-$4.1M	-$3.5M	-$2.9M	-$29M
Value	-$102M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2019	11/2020	12/2021	12/2022	12/2023	TTM
Net Margins	-6%	-	23%	25%	-48%	-27%
ROA	-	-	-	25%	42%	41%
ROE	-	-	33%	24%	-18%	-21%

Bad Net Margins (-27.02%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2019	11/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	-	-	1.05	8.88	-31.67
Debt over Equity	-	-	1.01	0.6	0.68	0.69
Growth Stability	-	-	-	100%	-109%	-109%

Good Debt/FCF ratio (-31.67)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Good Debt/Equity ratio (0.69)

The company is not overleveraged and has a good balance between equity and debt.

Bad Graham’s Stability (-109%)

The company has a bad stability in its earnings, which is a sign of a bad competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2019	11/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	-	-	10%	-67%	-22%
Earnings YoY growth	-	145%	-974%	21%	-163%	-3%
Equity YoY growth	-	-	-	66%	-13%	69%
FCF YoY growth	-	-	-	47%	-88%	-8%